Drug Profile


Alternative Names: MG-516; MG-91516; MGCD-516

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator MethylGene
  • Developer Columbia University; Mirati Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Eph family receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c met inhibitors; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Proto-oncogene protein c-mer inhibitors; Receptor protein-tyrosine kinase antagonists; RON protein inhibitors; TIE 2 receptor antagonists; Tropomyosin-related kinase antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liposarcoma; Non-small cell lung cancer; Soft tissue sarcoma
  • Phase I Solid tumours
  • Phase Unknown Renal cell carcinoma

Most Recent Events

  • 10 Jan 2017 Mirati Therapeutics and M.D. Anderson Cancer Center plan a phase I/II trial for Renal cell carcinoma (Metastatic disease, Late-stage disease, Combination therapy, Second-line therapy or greater) in USA (PO) (NCT03015740)
  • 06 Jan 2017 Investigation in Renal cell carcinoma in USA (PO) before January 2017
  • 05 Jan 2017 Efficacy data from a phase Ib trial in Solid tumours released by Mirati Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top